Item 8.01. Other Events.
On April 13, Soligenix, Inc. (the "Company") issued a press release announcing
planned conference presentations scheduled during April and May 2021. The
presentations will focus on the HyBryte™ (SGX301 or synthetic hypericin)
cutaneous T-cell lymphoma (CTCL) program, including elaboration on previously
released efficacy and safety outcomes in the Phase 3 FLASH (Fluorescent Light
Activated Synthetic Hypericin) study, and will provide an update on the CiVax™
(COVID-19 subunit vaccine) program, including review of data from pre-clinical
studies.
The full text of the press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press release of Soligenix, Inc. dated April 13, 2021.
1
© Edgar Online, source Glimpses